Ava Homiar

Ava Homiar

Auto-generated profile, based on publicly available information

Ava Homiar

Department of Psychiatry Oxford England University of Oxford

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2025 in BMJ Mental Health
Verified
Journal Article
Open access
PDF file
AHAva Homiar
Ava Homiar
JTJames Thomas
James Thomas
EOEdoardo G Ostinelli
Edoardo G Ostinelli
JKJaycee Kennett
Jaycee Kennett
CFClaire Friedrich
Claire Friedrich
ACAndrea Cipriani
Andrea Cipriani
Background: Living systematic reviews (LSRs) maintain an updated summary of evidence by incorporating newly published research. While they improve review currency, repeated screening and selection of new references make them labourious and difficult to maintain. Large language models (LLMs) show promise in assisting with screening and data extraction, but more work is needed to achieve the high accuracy required for evidence that informs clinical and policy decisions. Objective: The study evaluated the effectiveness of an LLM (GPT-4o) in title and abstract screening compared with human reviewers. Methods: Human decisions from an LSR on prodopaminergic interventions for anhedonia served as the reference standard. The baseline search results were divided into a development and a test set. Prompts guiding the LLM’s eligibility assessments were refined using the development set and evaluated on the test set and two subsequent LSR updates. Consistency of the LLM outputs was also assessed. Results: Prompt development required 1045 records. When applied to the remaining baseline 11 939 records and two updates, the refined prompts achieved 100% sensitivity for studies ultimately included in the review after full-text screening, though sensitivity for records included by humans at the title and abstract stage varied (58–100%) across updates. Simulated workload reductions of 65–85% were observed. Prompt decisions showed high consistency, with minimal false exclusions, satisfying established screening performance benchmarks for systematic reviews. Conclusions: Refined GPT-4o prompts demonstrated high sensitivity and moderate specificity while reducing human workload. This approach shows potential for integrating LLMs into systematic review workflows to enhance efficiency.

11 April 2024 in Wellcome Open Research
Verified
Journal Article
Open access
SSSpyridon Siafis
Spyridon Siafis
VCVirginia Chiocchia
Virginia Chiocchia
MMMalcolm R. Macleod
Malcolm R. Macleod
CACharlotte Austin
Charlotte Austin
AHAva Homiar
Ava Homiar
SLStefan Leucht
Stefan Leucht
Background Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods We co-produced a living systematic review of controlled studies examining TAAR1 agonists in individuals (with or without psychosis/schizophrenia) and relevant animal models. Two independent reviewers identified studies in multiple electronic databases (until 17.11.2023), extracted data, and assessed risk of bias. Primary outcomes were standardised mean differences (SMD) for overall symptoms in human studies and hyperlocomotion in animal models. We also examined adverse events and neurotransmitter signalling. We synthesised data with random-effects meta-analyses. Results Nine randomised trials provided data for two TAAR1 agonists (ulotaront and ralmitaront), and 15 animal studies for 10 TAAR1 agonists. Ulotaront and ralmitaront demonstrated few differences compared to placebo in improving overall symptoms in adults with acute schizophrenia (N=4 studies, n=1291 participants; SMD=0.15, 95%CI: -0.05, 0.34), and ralmitaront was less efficacious than risperidone (N=1, n=156, SMD=-0.53, 95%CI: -0.86, -0.20). Large placebo response was observed in ulotaront phase-III trials. Limited evidence suggested a relatively benign side-effect profile for TAAR1 agonists, although nausea and sedation were common after a single dose of ulotaront. In animal studies, TAAR1 agonists improved hyperlocomotion compared to control (N=13 studies, k=41 experiments, SMD=1.01, 95%CI: 0.74, 1.27), but seemed less efficacious compared to dopamine D2 receptor antagonists (N=4, k=7, SMD=-0.62, 95%CI: -1.32, 0.08). Limited human and animal data indicated that TAAR1 agonists may regulate presynaptic dopaminergic signalling. Conclusions TAAR1 agonists may be less efficacious than dopamine D2 receptor antagonists already licensed for schizophrenia. The results are preliminary due to the limited number of drugs examined, lack of longer-term data, publication bias, and assay sensitivity concerns in trials associated with large placebo response. Considering their unique mechanism of action, relatively benign side-effect profile and ongoing drug development, further research is warranted. Registration PROSPERO-ID:CRD42023451628.

27 August 2022 in Scientific Data
Verified
Journal Article
Open access
PDF file
APAbhishek Pratap
Abhishek Pratap
AHAva Homiar
Ava Homiar
LWLuke Waninger
Luke Waninger
CHCalvin Herd
Calvin Herd
CSChristine Suver
Christine Suver
PAPat Areán
Pat Areán
Most people with mental health disorders cannot receive timely and evidence-based care despite billions of dollars spent by healthcare systems. Researchers have been exploring using digital health technologies to measure behavior in real-world settings with mixed results. There is a need to create accessible and computable digital mental health datasets to advance inclusive and transparently validated research for creating robust real-world digital biomarkers of mental health. Here we share and describe one of the largest and most diverse real-world behavior datasets from over two thousand individuals across the US. The data were generated as part of the two NIMH-funded randomized clinical trials conducted to assess the effectiveness of delivering mental health care continuously remotely. The longitudinal dataset consists of self-assessment of mood, depression, anxiety, and passively gathered phone-based behavioral data streams in real-world settings. This dataset will provide a timely and long-term data resource to evaluate analytical approaches for developing digital behavioral markers and understand the effectiveness of mental health care delivered continuously and remotely.

23 May 2025 in Wellcome Open Research
Verified
Journal Article
Open access
JKJaycee Kennett
Jaycee Kennett
CFClaire Friedrich
Claire Friedrich
VCVirginia Chiocchia
Virginia Chiocchia
SBSimon E. Blackwell
Simon E. Blackwell
TFToshi Furukawa
Toshi Furukawa
ACAndrea Cipriani
Andrea Cipriani
Background Social anxiety is a heightened fear and discomfort in social situations. Cases of elevated distress and impaired functioning can lead to a clinical diagnosis of social anxiety disorder. Altering cognitive biases associated with social anxiety has been suggested as potentially beneficial; however, little is known about the comparative effectiveness of such interventions. The aim of this living systematic review is to examine the efficacy of cognitive bias modification for reducing social anxiety. Methods We will search multiple electronic databases for randomised controlled trials evaluating the efficacy of cognitive bias modification for people diagnosed with social anxiety and people exposed to a social stressor. The primary outcome will be change in social anxiety related symptoms; secondary outcomes will be changes in social functioning and quality of life and adverse events. Study selection, data extraction and risk of bias assessment will be done by at least two reviewers using pre-defined tools. We will synthesise data from people with social anxiety diagnosis and those subjected to a simulated social stressor separately using random effects meta-analyses. Heterogeneity will be evaluated by investigating characteristics of included studies and we will conduct a network meta-analysis in order to compare the efficacy of subtypes of cognitive bias modification for social anxiety disorder. We will appraise the strength of the evidence for each outcome by reviewing the overall association, internal and external validity, and reporting biases. Where data allows, we will triangulate the evidence from both sources with a multidisciplinary group of experts. We will also descriptively report factors reported to mediate cognitive bias modification, The review will begin in living mode and the database search will be rerun every three months to identify potential new evidence. We will co-produce this review with members of a global lived experience advisory board. This protocol was registered on 15.10.2024 (CRD42024601380)..

7 November 2024 in Wellcome Open Research
Verified
Journal Article
Open access
JKJaycee Kennett
Jaycee Kennett
CFClaire Friedrich
Claire Friedrich
VCVirginia Chiocchia
Virginia Chiocchia
SBSimon E. Blackwell
Simon E. Blackwell
TFToshi Furukawa
Toshi Furukawa
ACAndrea Cipriani
Andrea Cipriani
Background Social anxiety is a heightened fear and discomfort in social situations which can be experienced in varying degrees of severity. Cases of elevated distress and impaired functioning and quality of life can lead to a clinical diagnosis of social anxiety disorder. Altering cognitive biases associated with social anxiety has been suggested as potentially beneficial; however, little is known about the comparative effectiveness of such interventions. The aim of this living systematic review is to examine the efficacy of cognitive bias modification for reducing social anxiety, including in people who have not been diagnosed with the disorder. Methods We will search multiple electronic databases for randomised controlled trials evaluating the efficacy of cognitive bias modification for people diagnosed with social anxiety and people exposed to a simulated social stressor. The primary outcome will be change in social anxiety related symptoms; secondary outcomes will be changes in social functioning and quality of life and adverse events. Study selection, data extraction and risk of bias assessment will be done by at least two reviewers using pre-defined tools. We will synthesise data from people with social anxiety diagnosis and those subjected to a simulated social stressor separately using random effects meta-analyses. Heterogeneity will be evaluated by investigating characteristics of included studies. We will appraise the strength of the evidence for each outcome by reviewing the overall association, internal and external validity, and reporting biases. Where data allows, we will triangulate the evidence from both sources with a multidisciplinary group of experts. The review will begin in living mode and the database search will be rerun every three months to identify and integrate potential new evidence. We will co-produce this review with members of a global lived experience advisory board. This protocol was registered with PROSPERO (CRD42024601380) on 15.10.2024.

8 September 2025 in JMIR Preprints
Verified
Preprint
Open access
KCKatherine Anne Comtois
Katherine Anne Comtois
PSPayton Smythe
Payton Smythe
AKAmanda Kerbrat
Amanda Kerbrat
EKEthan Hyungkeun Kim
Ethan Hyungkeun Kim
NCNatalie Crouch
Natalie Crouch
PAPatricia A Arean
Patricia A Arean
BACKGROUND Social media and search engine tech companies, such as Google, use the wealth of data at their disposal to create algorithms to predict suicide risk, and provide interventions based on company policies and outputs from these algorithms. Neither the details of these algorithms or their accuracy in risk prediction are shared with the public, thus research is needed to verify whether algorithms applied to search engine data can accurately predict suicide risk in a platform user. The onus is on researchers to study the utility of these data for prediction, which requires donation of search data from people with lived experience of suicidal thoughts and behavior. There is little guidance, however, from the research community or tech companies as to how to best assist participants in sharing their data easily and securely. OBJECTIVE This paper describes study methods and experiences recruiting and retaining participants in a year long, fully remote prospective study of suicide prediction in people with variable risk for suicide, using Google Search data. METHODS We have recruited 485 United States dwelling and English-speaking adults who fall into one of 3 categories: participants with a suicide attempt in the past year, participants with a lifetime suicide attempt but not one in the past year, and participants with no lifetime suicide attempt. RESULTS We describe important data supporting the methods we used to recruit a remote sample of participants with risk for suicide, Google Search data quality, amount of fraudulent acting, and retention at each study phase and follow up assessment. CONCLUSIONS Despite past success with remote clinical research methods, we found that recruitment can be significantly hampered by fraudulent acting, despite the use of state-of-the-art methods to mitigate this problem. Further, the ability to acquire useful Google Search data is extremely challenging and necessitates the use of technical assistance and continuous monitoring of Google’s Takeout data structure to ensure accurate data downloads. The solutions we provide for this type of research should be helpful for future endeavors. However, research is still limited by the barriers to obtaining data from technology companies. CLINICALTRIAL Not applicable – not a clinical trial